Literature DB >> 20940398

CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes.

Rinke Bos1, Linda A Sherman.   

Abstract

CD4 help for CD8(+) T lymphocytes prevents tolerance and promotes the survival of effector and memory CD8(+) T cells. Here, we describe additional helper functions that require CD4(+) T cells within the tumor environment. CD8(+) T-cell recruitment, proliferation, and effector function within the tumor were greatly enhanced by tumor-specific CD4(+) T cells. Recruitment of CD8(+) T cells was accelerated by IFN-γ-dependent production of chemokines. Production of interleukin-2 by tumor resident CD4(+) T cells enhanced CD8(+) T-cell proliferation and upregulated expression of granzyme B. These results highlight a novel role for tumor-specific CD4(+) T cells in promoting CD8(+) T-cell recruitment and cytolytic function, two previously unappreciated aspects of tumor-specific CD4 help. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940398      PMCID: PMC2970736          DOI: 10.1158/0008-5472.CAN-10-1322

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming.

Authors:  Vadim Y Taraban; Tania F Rowley; David F Tough; Aymen Al-Shamkhani
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

2.  TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help.

Authors:  Sandra Hervas-Stubbs; Aurélie Olivier; Florence Boisgerault; Nathalie Thieblemont; Claude Leclerc
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

3.  Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells.

Authors:  S B Justin Wong; Rinke Bos; Linda A Sherman
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

Review 4.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.

Authors:  Steven A Rosenberg; Richard M Sherry; Kathleen E Morton; William J Scharfman; James C Yang; Suzanne L Topalian; Richard E Royal; Udai Kammula; Nicholas P Restifo; Marybeth S Hughes; Douglas Schwartzentruber; David M Berman; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White; Seth M Steinberg
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

6.  STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors.

Authors:  Grégory Verdeil; Denis Puthier; Catherine Nguyen; Anne-Marie Schmitt-Verhulst; Nathalie Auphan-Anezin
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

7.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

Authors:  Ronald J Buckanovich; Andrea Facciabene; Sarah Kim; Fabian Benencia; Dimitra Sasaroli; Klara Balint; Dionysios Katsaros; Anne O'Brien-Jenkins; Phyllis A Gimotty; George Coukos
Journal:  Nat Med       Date:  2008-01-06       Impact factor: 53.440

8.  Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy.

Authors:  Grégory Verdeil; Kristi Marquardt; Charles D Surh; Linda A Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

9.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

Authors:  Matthew A Williams; Aaron J Tyznik; Michael J Bevan
Journal:  Nature       Date:  2006-06-15       Impact factor: 49.962

10.  Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.

Authors:  K E Cole; C A Strick; T J Paradis; K T Ogborne; M Loetscher; R P Gladue; W Lin; J G Boyd; B Moser; D E Wood; B G Sahagan; K Neote
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  168 in total

1.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

2.  Engineered Materials for Cancer Immunotherapy.

Authors:  Alexander S Cheung; David J Mooney
Journal:  Nano Today       Date:  2015-08-01       Impact factor: 20.722

3.  Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Authors:  Jashodeep Datta; Cinthia Rosemblit; Erik Berk; Lori Showalter; Prachi Namjoshi; Rosemarie Mick; Kathreen P Lee; Andrew M Brod; Rachel L Yang; Rachel R Kelz; Elizabeth Fitzpatrick; Clifford Hoyt; Michael D Feldman; Paul J Zhang; Shuwen Xu; Gary K Koski; Brian J Czerniecki
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 4.  Dendritic Cell-Based Cancer Vaccines.

Authors:  Patricia M Santos; Lisa H Butterfield
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Cooperation of CD4+ T cells and CD8+ T cells and release of IFN-γ are critical for antileukemia responses of recipient mice treated by microtransplantation.

Authors:  Li Wang; Fan Du; Hongxiang Wang; Conghua Xie
Journal:  Exp Ther Med       Date:  2017-11-22       Impact factor: 2.447

7.  Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.

Authors:  Shaun O'Brien; Rajan M Thomas; Gerald B Wertheim; Fuqin Zhang; Hao Shen; Andrew D Wells
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

8.  Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

Authors:  Christian A Bauer; Edward Y Kim; Francesco Marangoni; Esteban Carrizosa; Natalie M Claudio; Thorsten R Mempel
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

Review 9.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

10.  Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes.

Authors:  Aikaterini Hatzioannou; Saba Nayar; Anastasios Gaitanis; Francesca Barone; Constantinos Anagnostopoulos; Panayotis Verginis
Journal:  Oncoimmunology       Date:  2016-07-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.